TLR9-Induced Antitumor Properties Are Dependent on CD2, an Underutilized yet Potent T Cell Costimulation Protein for Cancer Immunotherapies

Engineering technologies to enrich optimal phenotypes in CAR T cells

Differentiation fate of stem-like CD4 T cells control CD8 T cell immunity to cancer

Mechanisms of efficacy and toxicity of immune checkpoint inhibitors in human cancer patients

Characterization of Novel SMAD4 Protein-Protein Interactions in Pancreatic Cancer

MERTK inhibition selectively activates a DC – T-cell axis to provide anti-leukemia immunity

CD8 T cell Activation In Cancer Is Comprised Of Two Distinct Phases

Tumor Membrane Vesicles as a Personalized Vaccine Immunotherapy Platform for Cancer